BioSyent (CVE:RX) Share Price Passes Below Fifty Day Moving Average - Time to Sell?

Key Points

• BioSyent Inc. shares fell below the 50-day moving average of C$11.73, trading as low as C$11.44 with a 1.0% decline on Thursday.
• The company has a market capitalization of C$130.84 million and reported a PE ratio of 18.57, indicating its stock performance and valuation metrics.
• BioSyent specializes in developing and selling pharmaceutical and healthcare products, including treatments for iron deficiency anemia.

BioSyent Inc. (CVE:RX - ) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of C$11.73 and traded as low as C$11.44. BioSyent shares last traded at C$11.44, with a volume of 1,120 shares traded.

BioSyent Stock Down 1.0%

The stock has a market cap of C$130.84 million, a PE ratio of 18.57 and a beta of 0.93. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. The business has a 50-day moving average price of C$11.73 and a 200-day moving average price of C$11.18.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.